Evidence map›Paper›PMID 37068158›Full record

ArticleAccounts of chemical research2023

Digital and Absolute Assays for Low Abundance Molecular Biomarkers.

Chia-Wei Kuo, Andrew M Smith

Open access · greenAbstract read
In one paragraph

Article in Accounts of chemical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Real-Time Digital Micromotor Tracking-Enabled Ultrasensitive Immunoassay.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chia-Wei KuoDepartment of Bioengineering, University of Illinois Urbana-Champaign, Urbana, Illinois 61801, United States.
Andrew M SmithDepartment of Bioengineering, University of Illinois Urbana-Champaign, Urbana, Illinois 61801, United States.ORCID 0000-0002-0238-4816
University of Illinois Urbana-Champaign · US

Funding

Hyperplexed Quantum Dots for Multidimensional Cell Classification in Intact TissueR01EB032249 · NIBIB · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI SMITH, ANDREW MICHAEL · 2021 to 2024
$2.3M
Digital Multiplexed Analysis of Circulating Nucleic Acids in Small-Volume Blood SpecimensR01EB032725 · NIBIB · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI KOHLI, MANISH, SMITH, ANDREW MICHAEL · 2022 to 2025
$2.2M
Daily Quantification of Cancer-Associated Exosomal miRNA in Patient Blood by Photonic Crystal-Enhanced Quantum Dot EmissionR01CA227699 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI KOHLI, MANISH, SMITH, ANDREW MICHAEL · 2018 to 2022
$1.8M
Advanced Molecular Probes and Cell Engineering Tools for Accurate Single-Molecule Analysis of Signaling in Individual CellsR01GM131272 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI SMITH, ANDREW MICHAEL · 2019 to 2022
$1.1M
NCI NIH HHS R01 CA227699NIBIB NIH HHS R01 EB032249NIBIB NIH HHS R01 EB032725NIGMS NIH HHS R01 GM131272
6 · The paper itself

Abstract

There has been a recent surge of advances in biomolecular assays based on the measurement of discrete molecular targets as opposed to signals averaged across molecular ensembles. Many of these "digital" assay designs derive from now-mature technologies involving single-molecule imaging and microfluidics and provide an assortment of new modalities to quantify nucleic acids and proteins in biospecimens such as blood and tissue homogenates. A primary new benefit is the robust detection of trace analytes at attomolar to femtomolar concentrations for which many ensemble assays cannot distinguish signals above noise levels. In addition, multiple biomolecules can be differentiated within a mixture using optical barcodes, with much faster and simpler readouts compared with sequencing methods. In ideal digital assays, signals should, in theory, further represent absolute molecular counts, rather than relative levels, eliminating the need for calibration standards that are the mainstay of typical assays. Several digital assay platforms have now been commercialized but challenges hinder the adoption and diversification of these new formats, as there are broad needs to balance sensitivity and dynamic range of detection, increase analyte multiplexing, improve sample throughput, and reduce cost. Our lab and others have developed technologies to address these challenges by redesigning molecular probes and labels, improving molecular transport within detection focal volumes, and applying solution-based readout methods in flow.This Account describes the principles, formats, and design constraints of digital biomolecular assays that apply optical labels toward the goal of simple and routine target counting that may ultimately approach absolute readout standards. The primary challenges can be understood from fundamental concepts in thermodynamics and kinetics of association reactions, mass transport, and discrete statistics. Major advances include (1) new inorganic nanocrystal probes for more robust counting compared with dyes, (2) diverse molecular amplification tools that endow attachment of numerous labels to single targets, (3) specialized surfaces with patterned features for electromagnetic coupling to labels for signal amplification, (4) surface capture enhancement methods to concentrate targets through disruption of diffusion depletion zones, and (5) flow counting in which analytes are rapidly counted in solution without pull-down to a surface. Further progress and integration of these tools for biomolecular counting could improve the precision of laboratory measurements in life sciences research and benefit clinical diagnostic assays for low abundance biomarkers in limiting biospecimen volumes that are out of reach of traditional ensemble-level bioassays.

Indexed as

Nucleic AcidsBiomarkersColoring AgentsMicrofluidicsProteinsBiomarkersColoring AgentsNucleic AcidsProteins

Identifiers

PMID37068158
PMCPMC10163903
OpenAlexW4366142835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.